Amphastar Pharmaceuticals Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while iShares 20 Plus Year Treasury Bond ETF trades at $82.27. The key difference: Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMPH | TLT | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | — |
52-Week High | $30.81 | $92.06 |
52-Week Low | $16.87 | $82.05 |
Enterprise Value | $1.26B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
TLT trades at $82.76, up 0.29% on the day, while technical indicators signal a bearish trend with moving averages showing 11 sell signals versus 2 buy signals. The ETF faces pressure from rising Treasury yields and concerns about U.S. debt levels nearing $40 trillion. Recent institutional activity includes Ferguson Shapiro LLC purchasing 37,900 shares, indicating some professional interest despite the challenging environment.
The outlook remains cautious as rising oil prices and inflation concerns continue to pressure long-term bond yields higher. Investment opportunities exist for income-focused investors through TLT's dividend payments, but risks include Federal Reserve policy uncertainty and geopolitical tensions affecting Treasury markets.
Trailing returns across standard periods
Latest headlines on both assets
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →